Is autologous stem cell transplantation still the backbone of multiple myeloma treatment?
Upcoming trials for DLBCL: R-CHOP with acalabrutinib and obinutuzumab with checkpoint inhibitor
Renal complications in multiple myeloma - trials and next steps
Dr Moorman's highlights on mixed phenotype acute leukemia (MPAL) from ASH 2016
How is the landscape of Hodgkin lymphoma therapy changing?